Shares of Marksans Pharma Ltd gained 1.24% to Rs 189.11 in Thursday’s trade after the company announced that its UK-based subsidiary, Relonchem Ltd, received marketing authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its Exemestane 25mg film-coated tablets, a cancer treatment drug.
Regulatory approval and product details
The approval marks a significant milestone for Marksans Pharma’s oncology portfolio in the UK market. The Exemestane 25mg tablets are primarily used in the treatment of breast cancer, particularly in postmenopausal women, and are expected to enhance the company’s product mix in the regulated markets.
The company stated that this authorization strengthens Relonchem’s position as a trusted generic medicines supplier in the UK, while expanding its therapeutic footprint in oncology.
Earlier in October 2025, Relonchem also secured UK MHRA approval for Clonidine 100 microgram tablets and Clonidine Hydrochloride 25 microgram tablets, used for hypertension and certain pain management therapies.
Upcoming financial results
Marksans Pharma informed exchanges that its Board of Directors will meet on November 13, 2025, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Q2 FY26).
The company has been consistently expanding its presence across Europe through regulatory filings and new product launches, positioning itself as a mid-sized Indian pharmaceutical player with strong UK and US market exposure.
Stock market reaction
At 9:20 AM, the stock was quoting at Rs 189.10, up Rs 2.35 or 1.26% on the BSE, after opening higher at Rs 188.11. The stock touched an intraday high of Rs 193.65, with a market capitalization of Rs 8,573 crore and trading volume exceeding 1.1 million shares on the NSE.
Investors reacted positively to the regulatory update, viewing it as a potential growth catalyst for the company’s international sales in the coming quarters.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
